Overview

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
0
Participant gender:
All
Summary
Investigators will be determining whether a once weekly injectable medication Bydureon versus placebo is able to reduce the development of atherosclerosis. Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies will provide novel information about the temporal relationship between Bydureon induced changes in risk factors, endothelial function and atherosclerosis progression.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Phoenix VA Health Care System
Treatments:
Exenatide
Criteria
Inclusion Criteria:

- males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on
diet only

- take stable doses of oral antihyperglycemic agents with or without long-acting insulin

- must have a regular primary care provider (PCP) that is amenable to patient study
participation and will facilitate (blinded to the treatment) the research team's study
protocol efforts

Exclusion Criteria:

- type 1 diabetes mellitus (T1DM)

- current or recent glucagon-like peptide 1 receptor (GLP-1R) agonist use

- contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus
inappropriate for MRI exam)

- screening carotid ultrasound plaque thickness of <0.75 mm, prior or anticipated
carotid stenting or endarterectomy

- recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g.,
pancreatitis, severe renal disease) or personal or family history of medullary thyroid
carcinoma

- patients with Multiple Endocrine Neoplasia syndrome type 2

- serious hypersensitivity to exenatide or any product components

- severe gastrointestinal disease, or pregnancy